Benuvia Operations Partners with Avernus Pharma to Launch SYNDROS in GCC Region

Benuvia Operations and Avernus Pharma Join Forces

Benuvia Operations, LLC, a prominent global contract development and manufacturing organization, has announced an exciting new partnership with Avernus Pharma. This collaboration centers around a licensing agreement for SYNDROS® (dronabinol), aimed at enhancing healthcare within the Gulf Cooperation Council (GCC) region.

The Significance of the Partnership

Under this agreement, Avernus Pharma is set to become the exclusive supplier of SYNDROS® across several GCC countries, which include Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. This move follows the crucial approval from the Gulf Central Committee for Drug Registration (GCC-DR), marking a significant step in expanding the availability of this crucial pharmaceutical product.

SYNDROS® is uniquely positioned as the first and only FDA-approved oral solution of CII tetrahydrocannabinol (THC), specifically designed to combat chemotherapy-induced nausea and vomiting (CINV) in adults who have not seen improvement with standard antiemetic treatments. It also addresses anorexia associated with weight loss in AIDS patients, providing desperately needed relief.

Insights from the Leaders

Terry Novak, CEO of Benuvia, expressed enthusiasm about the collaboration, stating, “This partnership with Avernus represents a significant milestone in our mission to make SYNDROS® available to more patients worldwide.” He emphasized Avernus's strong reputation in the local pharmaceutical market, which he believes will be instrumental in the successful commercialization of SYNDROS® in the Gulf region.

Dr. Ziad Amir Saleh, CEO of Avernus Pharma Al Ain Medical Store, echoed these sentiments by stating that the introduction of SYNDROS® symbolizes a groundbreaking moment for chemotherapy patients across the GCC. He highlighted the importance of this medication, reflecting a new era of hope and innovation in oncology care. Dr. Malath Jamous, Director of Avernus Pharma, added depth to this insight by noting that the agreement signifies a monumental step forward in transforming the lives of patients enduring the severe side effects of chemotherapy.

About Benuvia Operations

Benuvia Operations is a trailblazer in pharmaceutical contract development and manufacturing, dedicated to helping biotechnology and pharmaceutical companies deliver therapies that significantly improve patient outcomes. Their state-of-the-art facility in Round Rock, Texas, specializes in the production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms, emphasizing their expertise in cannabinoids and other controlled substances.

The multi-faceted approach of Benuvia ensures comprehensive support for companies throughout the drug development lifecycle—from API synthesis to clinical trial supply and commercial manufacturing.

About Avernus Pharma

Avernus Pharma stands as a key player in the Middle East's pharmaceutical landscape, providing innovative healthcare solutions to patients while striving for excellence in accessibility. The company collaborates closely with global pharmaceutical partners to deliver advanced therapeutic options and remains committed to patient care.

For more information about SYNDROS®, visit Syndros.

Conclusion

The collaboration between Benuvia Operations, LLC and Avernus Pharma not only signifies a pivotal moment for patients in the GCC but also showcases the commitment to improving oncology care through innovative solutions. As more patients gain access to SYNDROS®, the hope for enhanced treatment experiences in such challenging conditions becomes a tangible reality.